Internet Archive Scholar

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter
2014 Diabetes Care  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.0 MB)
https://web.archive.org/web/20180722133944/http://care.diabetesjournals.org/content/diacare/37/8/2317.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL. The file type is application/pdf.

OBJECTIVE GLP-1 receptor agonists may provide an alternative to prandial insulin for advancing basal insulin therapy. Harmony 6 was a randomized, open-label, activecontrolled trial testing once-weekly albiglutide vs. thrice-daily prandial insulin lispro as an add-on to titrated once-daily insulin glargine. RESEARCH DESIGN AND METHODS Patients taking basal insulin (with or without oral agents) with HbA 1c 7-10.5% (53-91 mmol/mol) entered a glargine standardization period, followed by
more » ... n to albiglutide, 30 mg weekly (n = 282), subsequently uptitrated to 50 mg, if necessary, or thrice-daily prandial lispro (n = 281) while continuing metformin and/or pioglitazone. Glargine was titrated to fasting plasma glucose of <5.6 mmol/L, and lispro was adjusted based on glucose monitoring. The primary end point was the difference in the HbA 1c change from baseline at week 26. RESULTS At week 26, HbA 1c decreased from baseline by 20.82 6 SE 0.06% (9.0 mmol/mol) with albiglutide and 20.66 6 0.06% (7.2 mmol/mol) with lispro; treatment difference, 20.16% (95% CI 20.32 to 0.00; 1.8 mmol/mol; P < 0.0001), meeting the noninferiority end point (margin, 0.4%). Weight decreased with albiglutide but increased with lispro (20.73 6 0.19 kg vs. +0.81 6 0.19 kg). The mean glargine dose increased from 47 to 53 IU (albiglutide) and from 44 to 51 IU (lispro). Adverse events for albiglutide versus lispro included severe hypoglycemia (0 vs. 2 events), documented symptomatic hypoglycemia (15.8% vs. 29.9%), nausea (11.2% vs. 1.4%), vomiting (6.7% vs. 1.4%), and injection site reactions (9.5% vs. 5.3%). CONCLUSIONS Weekly albiglutide is a simpler therapeutic option than thrice-daily lispro for advancing basal insulin glargine therapy, resulting in comparable HbA 1c reduction with weight loss and lower hypoglycemia risk.
doi:10.2337/dc14-0001 pmid:24898300 fatcat:azueaxjqxjd5telrrlyybcaizm
Citation

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter. "Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro." Diabetes Care 37.8 (2014) 2317-2325